(Q36394352)

13 August 2017

1 reference

title

The metabolic basis of atherogenic dyslipidemia (English)

1 reference

13 August 2017

1 reference

1 reference

Aaron I Vinik

1

1 reference

13 August 2017

publication date

1 January 2005

1 reference

13 August 2017

1 reference

13 August 2017

volume

7

1 reference

13 August 2017

issue

2-3

1 reference

13 August 2017

page(s)

27-35

1 reference

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980065-1

7 January 2021

Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980065-1

7 January 2021

Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980065-1

7 January 2021

Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980065-1

7 January 2021

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980065-1

7 January 2021

Twelve-year incidence of coronary heart disease in middle-aged adults during the era of hypertensive therapy: the Framingham offspring study.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980065-1

7 January 2021

Management of atherogenic dyslipidemia of the metabolic syndrome: evolving rationale for combined drug therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980065-1

7 January 2021

Relation between atherogenic dyslipidemia and the Adult Treatment Program-III definition of metabolic syndrome (Genetic Epidemiology of Metabolic Syndrome Project).

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980065-1

7 January 2021

Factor analysis of metabolic syndrome using directly measured insulin sensitivity: The Insulin Resistance Atherosclerosis Study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980065-1

7 January 2021

Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980065-1

7 January 2021

Trends in waist circumference among U.S. adults

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980065-1

7 January 2021

Analysis of obesity and hyperinsulinemia in the development of metabolic syndrome: San Antonio Heart Study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980065-1

7 January 2021

Hyperinsulinemia as an independent risk factor for ischemic heart disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980065-1

7 January 2021

Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980065-1

7 January 2021

Mechanisms of fatty acid-induced inhibition of glucose uptake

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980065-1

7 January 2021

Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980065-1

7 January 2021

Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980065-1

7 January 2021

C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980065-1

7 January 2021

Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980065-1

7 January 2021

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980065-1

7 January 2021

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980065-1

7 January 2021

The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980065-1

7 January 2021

10.1016/S1098-3597(05)80065-1

Identifiers

DOI

1 reference

13 August 2017

1 reference